This is a working overview of analytical methods, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-25. Anything still debated is marked as such rather than presented as settled.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
In Syria, an Israeli airstrike on a copper plant near Aleppo killed 16 members of Iran-backed militias. Hezbollah said that it fired drones at the IDF's headquarters in the Galilee. It also claimed a drone attack in Metula. The IDF confirmed that two drones crashed in northern Israel while a third was intercepted. Acting Minister of Foreign Affairs of Iran made his first overseas visit as foreign minister to Lebanon, during which he confirmed that the Iranian government was engaged in negotiations with the United States hosted by Oman. Forest fires in northern Israel were erupted the entire week which reportedly resulted in 2,500 acres of land burnt and the hospitalization of six Israeli soldiers and five civilians due to smoke inhalation. On 11 June, an Israeli strike on a command and control center in Jwaya killed senior Hezbollah commander Taleb Abdallah and three other militants. The next day, in response to Taleb's killing, Hezbollah launched a barrage of about 90 rockets into Israel targeting an IDF factory, military headquarters in Ein Zeitim and Ami'ad, and an air surveillance station in Meron. It later fired another 70 at the Mount Meron area, and then ten more at Zar'it, bringing the total number of launches to 170. It increased to 215 by the late afternoon. On 13 June, Hezbollah fired 150 rockets and 30 UAVs at 15 targets in northern Israel and the Golan Heights. Amos Hochstein, a senior advisor to US President Joe Biden, arrived in Israel on 17 June to attempt to de-escalate tensions between Israel and Lebanese militias.
The back-end of the nuclear fuel cycle, mostly spent fuel rods, contains fission products that emit beta and gamma radiation, and actinides that emit alpha particles, such as uranium-234 (half-life 245 thousand years), neptunium-237 (2.144 million years), plutonium-238 (87.7 years) and americium-241 (432 years), and even sometimes some neutron emitters such as californium (half-life of 898 years for californium-251). These isotopes are formed in nuclear reactors. It is important to distinguish the processing of uranium to make fuel from the reprocessing of used fuel. Used fuel contains the highly radioactive products of fission (see high-level waste below). Many of these are neutron absorbers, called neutron poisons in this context. These eventually build up to a level where they absorb so many neutrons that the chain reaction stops, even with the control rods completely removed from a reactor. At that point, the fuel has to be replaced in the reactor with fresh fuel, even though there is still a substantial quantity of uranium-235 and plutonium present. In the United States, this used fuel is usually "stored", while in other countries such as Russia, the United Kingdom, France, Japan, and India, the fuel is reprocessed to remove the fission products, and the fuel can then be re-used. The fission products removed from the fuel are a concentrated form of high-level waste as are the chemicals used in the process. While most countries reprocess the fuel carrying out single plutonium cycles, India is planning multiple plutonium recycling schemes and Russia pursues closed cycle.
== Mechanism of action == Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2), which are responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter mechanism causes blood glucose to be eliminated through the urine. In combination with metformin, dapagliflozin at standard treatment dose of 10 mg daily lowered HbA1c by 0.54-0.84% (5.9-9.3 mmol/mol) when compared to metformin monotherapy in patients with inadequately controlled type 2 diabetes and normal renal function. Its protective effects in heart failure are attributed primarily to haemodynamic effects, where SGLT2 inhibitors potently reduce intravascular volume through osmotic diuresis and natriuresis. This consequently may lead to a reduction in preload and afterload, thereby alleviating cardiac workload and improving left ventricular function.
=== Absence of benefit === The potential benefit of using essential nutrient dietary supplements to lower the risk of diseases has been refuted by findings of no effect or weak evidence in numerous clinical reviews, such as for HIV, or tuberculosis.
==== Public vocational high schools ==== Lycée technique et professionnel Françoise de Grâce Lycée professionnel Jules Lecesne (Hotel trades and services) Lycée professionnel Jules Siegfried (Electronic and Mechanical trades) Lycée professionnel Antoine Laurent de Lavoisier (Transport and Logistics – Metallic structures – automobiles) Lycée professionnel Auguste Perret (Housing trades) Lycée professionnel Claude Monet (Accounting – Secretarial) Lycée professionnel Porte Océane (Accounting – Secretarial) Lycée professionnel Robert Schuman (Industry)
Sources: en.wikipedia.org
== See also == First 100 days of the second Trump presidency – Period from January to April 2025 List of executive actions by Donald Trump Lists of presidential trips made by Donald Trump (international trips) Second presidential transition of Donald Trump – Transfer of presidential power from Joe Biden to Donald Trump Timeline of the 2024 United States presidential election
=== Chicken and eggs === Japanese and South Korean authorities' tests on imported powdered eggs from China found melamine contamination. Japan found melamine in frozen fried chicken imported from China. The South Korean supplies were traced to two companies in Dalian. On 26 October, Hong Kong authorities discovered 4.7ppm melamine in eggs from Dalian. Hong Kong Secretary for Food and Health, York Chow, suspected the melamine came from feed given to the chickens that laid the eggs. On 29 October, Hong Kong authorities discovered a third batch of eggs containing excessive melamine. The Taiwanese Department of Health said that six batches of protein powder from Jilin and Dalian were found to contain 1.90 to 5.03ppm of melamine. Agriculture officials speculated that adulterated feed given to hens could explain melamine in eggs. The Web sites of Xinhua and People's Daily both carried a story from the Nanfang Daily that mixing melamine into animal feed was an "open secret" in the industry: melamine scrap was mixed into an inexpensive "protein powder" resold to feed suppliers. People in the trade interviewed by BusinessWeek also confirmed it was common practice, and had been going on for "years", with most believing it to be non-toxic to animals. Melamine dealers said after Sanlu, the government started clamping down on melamine sales to food processing companies or to manufacturers of animal feed.
== Applications == DNA sequencing can be used to determine the sequence of individual genes, larger genetic regions (i.e. clusters of genes or operons), full chromosomes, or entire genomes of any organism. DNA sequencing is also the most efficient way to indirectly sequence RNA or proteins (via their open reading frames). In fact, DNA sequencing has become a key technology in many areas of biology and other sciences such as medicine, forensics, and anthropology.
Tennessee marble, extracted from quarries on the city's periphery, was used in the construction of numerous monumental buildings across the country, earning Knoxville the nickname, "The Marble City." Knoxville's economy slowed in the early 1900s. Political factioning hampered revitalization efforts throughout much of the 20th century, though the creation of federal entities such as the Tennessee Valley Authority in the 1930s and the ten-fold expansion of the University of Tennessee helped keep the economy stable. Beginning in the late 1960s, a city council more open to change, along with economic diversification, urban renewal, and the hosting of the 1982 World's Fair, helped the city revitalize to some extent.
== Advocacy == AMP advocates for molecular professionals and the patients they serve. In the U.S. molecular genetics testing is governed by a wide range of regulations, including the Clinical Laboratory Improvement Act (CLIA), the Centers for Medicare and Medicaid, and the Food and Drug Administration, that impact the performance and reimbursement of medical laboratory services. Through its advocacy efforts, such as the AMP Economics Summit, AMP strives to modernize the regulatory environment. It works to inform the U.S. Congress and federal agencies regarding public policy issues affecting molecular pathology. AMP seeks to shape and promote policies that ensure broad and equitable patient access to appropriate laboratory testing. Internationally, AMP members are involved in advocating for appropriate molecular diagnostic testing in several countries around the world.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.